Pharmacology/Pharmaceutical Industry
[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19
11 Mar, 2021 | 08:41h | UTCPress release: Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Commentary: Eli Lilly’s combo therapy for COVID-19 cuts serious illness and death in large study – Reuters
State of the Art Review | Severe covid-19 pneumonia: pathogenesis and clinical management
11 Mar, 2021 | 08:37h | UTCSevere covid-19 pneumonia: pathogenesis and clinical management – The BMJ
More data suggesting a single dose of SARS-CoV-2 mRNA vaccine may be enough in seropositive individuals
11 Mar, 2021 | 08:18h | UTCRelated: Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection (studies and commentary) AND Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 – JAMA
Lab study shows Pfizer/BioNTech COVID-19 vaccine can also neutralize B.1.351, P1 and B.1.1.7 variants
10 Mar, 2021 | 08:43h | UTCNeutralizing Activity of BNT162b2-Elicited Serum – New England Journal of Medicine
Commentaries: Expert reaction to NEJM correspondence paper looking at the neutralising activity of the Pfizer-BioNTech vaccine against SARS-CoV-2 variants in the lab – Science Media Centre AND Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study – Reuters
Opinion | Why comparing Covid-19 vaccine efficacy numbers can be misleading
10 Mar, 2021 | 08:31h | UTCWhy comparing Covid-19 vaccine efficacy numbers can be misleading – Vox
Study Commentary | Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster
10 Mar, 2021 | 08:36h | UTCSingle-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster – The Lancet
Original study and news release: 3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval
Opinion | The Differences Between the Vaccines Matter
10 Mar, 2021 | 08:33h | UTCThe Differences Between the Vaccines Matter – Vox
A pandemic expert weighs in on the long road ahead for Covid-19 vaccine distribution
10 Mar, 2021 | 08:35h | UTCA pandemic expert weighs in on the long road ahead for Covid-19 vaccine distribution – STAT
RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia
9 Mar, 2021 | 02:29h | UTCShort-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)
Editorial: Rightsizing Treatment for Pneumonia in Children
Commentary: Five days of antibiotics fine for children with pneumonia – McMaster University
Commentary on Twitter (thread – click for more)
This is fantastic! In outpatient community acquired pneumonia (CAP) a 5 day course of amoxicillin is just as effective as a 10 day course. A small thread follow1/6https://t.co/ewceFEe4gw
— Ricardo Quinonez, MD (@QuinonezRicardo) March 8, 2021
Systematic review: (Ultra‐)long‐acting insulin analogs for people with type 1 diabetes mellitus
9 Mar, 2021 | 02:14h | UTC(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus – Cochrane Library
Colchicine and COVID-19: a Tale of Two Trials
9 Mar, 2021 | 02:51h | UTCColchicine and COVID-19: a Tale of Two Trials – CVCT CardioBrief
Study 1: RECOVERY trial: Colchicine arm stopped for lack of efficacy in patients hospitalized with COVID-19
Study 2: [Preprint] Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
RCT: Half-dose vs. full-dose Edoxaban in 14,014 patients with Atrial Fibrillation
7 Mar, 2021 | 19:13h | UTCCommentary: Lower Dose of Edoxaban Supported in ENGAGE-AF-TIMI 48 Analysis – TCTMD
RECOVERY trial: Colchicine arm stopped for lack of efficacy in patients hospitalized with COVID-19
7 Mar, 2021 | 20:16h | UTCCommentary: Cochicine does not improve mortality in COVID19 – St Emlyn’s
Commentary on Twitter
RECOVERY trial update:
Colchicine arm stopped for lack of efficacy in patients hospitalised with COVID-19.https://t.co/hcn9PytegJ pic.twitter.com/q09eddYXYL
— Martin Landray (@MartinLandray) March 5, 2021
RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19
7 Mar, 2021 | 20:15h | UTC
Commentary on Twitter
The PRINCIPLE trial publishes its first peer reviewed paper, showing results from the study of azithromycin as a treatment for Covid-19 in the community. @TheLancet #UrgentCovidResearch #PRINCIPLETrial
?https://t.co/qKRI5PVpQk pic.twitter.com/BVQztDSvSC— OxPrimaryCareSci (@OxPrimaryCare) March 5, 2021
WHO: The effects of virus variants on COVID-19 vaccines
7 Mar, 2021 | 20:09h | UTCThe effects of virus variants on COVID-19 vaccines – World Health Organization
[Medicine based on data leaks…] Oxford study indicates AstraZeneca vaccine is effective against SARS-CoV-2 Lineage P.1
7 Mar, 2021 | 19:48h | UTC
Commentary on Twitter
Reuters reporting on that leak that a lab study in Oxford for their vaccine (AstraZeneca) could stand up well to P1 ("Brazil" variant). Sounds like we'll know what they found soon?https://t.co/OvZebNk4gh (Corrected tweet. Thx @Bertrandization @CanadianOptom!)
— Hilda Bastian, PhD (@hildabast) March 6, 2021
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
7 Mar, 2021 | 19:43h | UTC
Commentary on Twitter (thread – click for more)
Very good and important new data on the UK variant and vaccine response
"B.1.1.7 is not a neutralization escape variant of concern for COVID-19 vaccines"
"B.1.1.7 is unlikely to increase the risk of SARS-CoV-2 re-infection"https://t.co/DWzwBUDwY3 @cellhostmicrobe pic.twitter.com/iQv7mL9MHq— Eric Topol (@EricTopol) March 4, 2021
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
5 Mar, 2021 | 08:53h | UTCCommentaries: Ivermectin: Yet Another Fad Runs Into The Brick Wall Known As “Actual Science” – Brief-19 AND Ivermectin doesn’t speed recovery from mild COVID-19, study shows – CIDRAP
How well does the AstraZeneca vaccine work? An expert reviews the current evidence
5 Mar, 2021 | 08:49h | UTC
Some experience delayed rash after Moderna shot, study says
5 Mar, 2021 | 08:44h | UTCSome Experience Delayed Rash After Moderna Shot, Study Says – Bloomberg
Original study: Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 – New England Journal of Medicine
RCT: Mixed findings with Terlipressin plus Albumin for the treatment of Type 1 hepatorenal syndrome
4 Mar, 2021 | 08:35h | UTCTerlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes
4 Mar, 2021 | 08:31h | UTC
The myth of ‘good’ and ‘bad’ Covid vaccines: Why false perceptions overlook facts, and could breed resentment
4 Mar, 2021 | 08:44h | UTC
Addressing Antibiotic Overuse in the Outpatient Setting: Lessons From Behavioral Economics
4 Mar, 2021 | 08:27h | UTC
Comprehensive review of topical analgesics for chronic pain
4 Mar, 2021 | 08:19h | UTCComprehensive Review of Topical Analgesics for Chronic Pain – Current Pain and Headache Reports